Blood Testing in Jihlava

IFCOR's Lyme Disease Antibody Screen detects both IgM and IgG antibodies against Borrelia burgdorferi — the bacterial pathogen transmitted by tick bites — using recombinant antigen-based serology. IgM antibodies appear 2–4 weeks after infection and indicate recent or active infection; IgG antibodies develop 4–8 weeks after infection and can persist for years, indicating past exposure. The Czech Republic is one of the highest-incidence Lyme disease regions in Europe due to its forested landscape and high Ixodes ricinus tick density, making this test a routine consideration after tick bites or unexplained flu-like symptoms, joint pain, or neurological symptoms in summer and autumn. Results are available the next business day without fasting.

IFCOR's four-disease STI blood screen tests for the four most significant sexually transmitted blood-borne infections — hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV Ig), HIV antibodies, and syphilis (RPR plus confirmatory TPHA) — from a single blood draw. These are the infections most commonly screened before sexual health check-ups, new relationships, or as pre-procedural requirements for some medical treatments. The panel requires no fasting and results are available the next business day. Negative results are meaningful only during the appropriate window period: HIV requires retesting if exposure was within the last 6 weeks.

The ALEX2 Comprehensive Allergy Panel tests IgE reactivity against 295 allergens — 117 standardised extract-level allergens plus 178 molecular (component-resolved) allergens — in a single blood sample. This is the most extensive allergy testing methodology available outside of specialist immunology centres, covering pollen (grasses, trees, weeds), house dust mites, pet dander, moulds, and a wide range of food allergens. By testing both extract-level and molecular allergen components simultaneously, ALEX2 distinguishes true primary sensitisation from cross-reactive false positives — a critical advantage over skin-prick testing or single-allergen IgE panels. Results within 1–2 weeks require physician interpretation to translate the 295 results into a meaningful clinical picture.

IFCOR's Thrombophilia Genetic Panel is a comprehensive coagulation and genetics screen for people at elevated risk of inherited blood-clotting disorders. It combines haematological coagulation markers (CBC, prothrombin time, aPTT, fibrinogen, D-dimers, antithrombin) with molecular PCR testing for the five most clinically significant thrombophilia mutations: Factor V Leiden, Prothrombin gene G20210A, Factor XIII, MTHFR C677T, MTHFR A1298C, and PAI-1 4G/5G. Unlike coagulation function tests alone, genetic testing identifies permanent inherited risk that does not normalise with treatment — enabling lifelong risk-aware decisions about anticoagulation, hormonal contraception, pregnancy management, and surgery. Informed consent is required. Results are available within two weeks.